Investigational drug · Phase 3
LM-302
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, Adenocarcinoma, Malignant Neoplasms of Digestive Organs.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
12
Any phase or sponsor naming "LM-302"
First trial start
2021
Nov 26, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LM-302", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
- Adenocarcinoma
- Malignant Neoplasms of Digestive Organs
- Advanced Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LM-302" as an intervention, largest first.
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.Pivotal-lookingRecruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07385703 · 752 participants (planned) · Start Apr 15, 2026 · Primary completion Oct 2028
Drug: LM-302 Injection; Tislelizumab and 2 more · For: Adenocarcinoma
Sites: Hefei, China; Wuhu, China; Beijing, China · 106 sites in all
LaNova Medicines Zhejiang Co., Ltd.Industry
NCT05934331 · 632 participants (planned) · Start Jul 27, 2023 · Primary completion Aug 6, 2031
Drug: LM-302; Toripalimab and 9 more · For: Malignant Neoplasms of Digestive Organs
Sites: Shanghai, China
- LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.Pivotal-lookingActive, not recruiting
LaNova Medicines Zhejiang Co., Ltd.Industry
NCT06351020 · 387 participants · Start Jun 24, 2024 · Primary completion Nov 10, 2026
Drug: LM-302; Apatinib and 1 more · For: Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Sites: Beijing, China; Shanghai, China
LaNova Medicines Zhejiang Co., Ltd.Industry
NCT05161390 · 153 participants · Start Nov 26, 2021 · Primary completion Jan 10, 2025
Drug: LM-302 Injection · For: Advanced Solid Tumor
Sites: Shanghai, China
Ruijin HospitalAcademic, hospital or other
NCT07569068 · 88 participants (planned) · Start Apr 21, 2026 · Primary completion Apr 30, 2028
Drug: Tislelizumab, LM-302 and S-1; Tislelizumab combined with oxaliplatin and S-1 · For: Gastric or Esophagogastric Junction Adenocarcinoma
Sites: Shanghai, China
- Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 AntibodyActive, not recruiting
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05994001 · 78 participants · Start Aug 1, 2023 · Primary completion May 1, 2026
Drug: cardonilizumab; LM-302 · For: Biliary Tract Cancer; Candonilimab; Claudin 18.2
Sites: Shanghai, China
Ruijin HospitalAcademic, hospital or other
NCT07556640 · 74 participants (planned) · Start Apr 17, 2026 · Primary completion Apr 30, 2028
Drug: LM-302, S-1, paclitaxel; LM-302, Cadonilimab, S-1, paclitaxel · For: Gastric Cancer Stage IV; Peritoneal Metastases From Gastric Cancer; Gastric or Esophagogastric Junction Adenocarcinoma
Sites: Shanghai, China
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT06587425 · 50 participants (planned) · Start Jul 31, 2024 · Primary completion Jul 31, 2025
Drug: LM-302+Candonilimab+Capecitabine · For: Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Shanghai, China
Ruijin HospitalAcademic, hospital or other
NCT06519591 · 40 participants (planned) · Start Feb 25, 2025 · Primary completion Jan 2027
Drug: Cadonilimab, LM-302, S-1, paclitaxel · For: Gastric Cancer Stage IV; Peritoneal Metastases
Sites: Shanghai, China
- Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic CancerNot yet recruiting
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07108504 · 30 participants (planned) · Start Aug 10, 2025 · Primary completion Aug 10, 2026
Drug: Gemcitabine; LM-302 · For: Pancreatic Cancer; Chemotherapy Effect
Newest research
PubMed records naming it or its code names, newest first.
- Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.
Bai C, Zheng Y, Sun M, et al. · Eur J Cancer 2025
- Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review).
Katoh M, Katoh M · Int J Mol Med 2024
- Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting.
Zhou KI, Strickler JH, Chen H · J Hematol Oncol 2024
Also in development for Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.